NCT03280056 - Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients | Biotech Hunter

Enrollment

196

Participants

Timeline

Start Date

August 28, 2017

Primary Completion Date

September 29, 2020

Study Completion Date

September 29, 2020

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

BIOLOGICAL

NurOwn® (MSC-NTF cells)

"NurOwn® (MSC-NTF): One course of treatment that includes three separate intrathecal injections of 100-125 x 10\^6 cells every 8 weeks~NurOwn® (MSC-NTF): Autologous, bone marrow-derived, mesenchymal stem cells secreting neurotrophic factors"

OTHER

Placebo

"One course of treatment that includes three separate intrathecal injections of Placebo every 8 weeks~Placebo: liquid solution in syringe for injection"

OTHER

Bone Marrow aspiration

Trial Locations (6)

55905

Mayo Clinic, Rochester

90048

Cedars-Sinai Medical Center, Los Angeles

92697

University of California Irvine Alpha Stem Cell Clinic, Irvine

94115

California Pacific Medical Center, San Francisco

02115

Massachusetts General Hospital, Boston

01655

University of Massachusetts Medical School, Worcester